Capital Impact Advisors, LLC Kura Oncology, Inc. Transaction History

Capital Impact Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 18, 2021	SELL	$24.75 - $39.14 $1.54 Million - $2.44 Million	-62,331 Closed	0 $0
Q2 2020 Aug 17, 2020	SELL	$7.95 - $18.81 $623,073 - $1.47 Million	-78,374 Reduced 55.7%	62,331 $1.02 Million
Q1 2020 May 15, 2020	BUY	$6.45 - $14.04 $53,928 - $117,388	8,361 Added 6.32%	140,705 $1.4 Million
Q4 2019 Feb 13, 2020	BUY	$12.97 - $15.94 $130,620 - $160,531	10,071 Added 8.24%	132,344 $1.82 Million
Q3 2019 Nov 14, 2019	BUY	$14.75 - $20.87 $296,106 - $418,965	20,075 Added 19.64%	122,273 $1.8 Million
Q2 2019 Jul 19, 2019	SELL	$14.71 - $19.79 $508,509 - $684,120	-34,569 Reduced 25.28%	102,198 $2.02 Million
Q4 2018 Mar 08, 2019	BUY	$10.6 - $17.49 $428,399 - $706,858	40,415 Added 41.95%	136,767 $1.84 Million
Q2 2018 Jul 25, 2018	BUY	$14.8 - $18.8 $245,680 - $312,080	16,600 Added 20.81%	96,352 $1.67 Million
Q1 2018 Apr 11, 2018	BUY	$14.5 - $23.4 $1.16 Million - $1.87 Million	79,752 New	79,752 $1.5 Million

185

81.8M

42.1K

34K

Ticker KURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,893,000
Market Cap $598M
Description
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.